David Hobson

• Patent Filing & Prosecution: David excels at putting in place and defending robust, valuable patents encompassing his clients’ key assets throughout the product lifecycle.
• IP Strategy: Leveraging his extensive patent drafting and portfolio management practice, he works closely with his clients’ commercial and scientific teams to map out optimal filing strategies to maximise patent exclusivity, and to guard against biosimilar threats.
• Freedom to Operate (FTO) & EPO Opposition: Given the competitive nature of the pharmaceutical field, David and his team perform regular competitor intelligence gathering and patent monitoring for clients, advise on high-value FTO matters, and represent clients in key offensive and defensive opposition and appeal proceedings.

• Ipsen Biopharm Limited v ReVance Therapeutics, Inc. (EP3368071)
• Mathys & Squire v Chugai Seiyaku Kabushiki Kaisha (EP2311492)
• Keltie LLP v AT Promotions Ltd (EP3193675)
• Allergan, Inc. v Ipsen Bioinnovation Limited (EP2677029) & Enlarged Board of Appeal Referral R 14/24
• Merz Pharma GmbH & Co. KGaA v Ipsen Bioinnovation Limited (EP2398495)
• Polymun Scientific Immunbiologische Forschung GmbH v Sterrenbeld Biotechnologie North America, Inc. (EP1124984)

David has a PhD in biochemistry from the Cancer Research UK London Research Institute (awarded by UCL).  His PhD focussed on the mechanism of transcription of convergent genes, including RNA polymerase II collision and resolution. The latter required the reconstitution of RNA polymerase transcription complexes in vitro from the purified eukaryotic polymerase complex, nucleic acids, and other factors. The associated scientific publication can be accessed here. 

David is a European Patent Attorney, Chartered UK Patent Attorney, UPC Representative, member of the European Patent Institute (EPI), and a fellow of the Chartered Institute of Patent Attorneys (CIPA).